Medtronic advances artificial pancreas research with new study

Medtronic has brought the development of a functioning artificial pancreas a step closer through a new clinical trial of related technology.

Results from the Aspire study have shown that its MiniMed Paradigm System with Low Glucose Suspend (LGS) automation is able to deliver reductions in the amount of time spent by patients below the low glucose threshold, compared to conventional pump therapy.

The new LGS technology is used by the device to suspend insulin delivery if the sensor glucose value is equal to or below the designated low threshold value.

Data from this trial will be used by the company to support regulatory approval of LGS technology in the US and could have further implications in the treatment of diabetes in future.

Dr Francine Kaufman, chief medical officer and vice-president of global clinical affairs for the diabetes business of Medtronic, said: "We are excited about this first step and are committed to advancing the insulin delivery, sensor technology and closed loop algorithms to commercialise an artificial pancreas."

Last month, the company published its financial report for 2011, highlighting a two percent annual increase in sales.